Takip et
Ahmet Emre Eşkazan
Ahmet Emre Eşkazan
Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine
istanbul.edu.tr üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature
A Murt, AE Eskazan, U Yılmaz, T Ozkan, MC Ar
Journal of medical virology 93 (1), 43, 2021
662021
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
RM Stone, RA Larson, H Doehner
The New England journal of medicine 377 (19), 1903-1903, 2017
642017
Dasatinib‐induced pulmonary arterial hypertension
N Özgür Yurttaş, AE Eşkazan
British Journal of Clinical Pharmacology 84 (5), 835-845, 2018
592018
Bone marrow transplantation for Behçet’s disease: a case report and systematic review of the literature
T Soysal, A Salihoğlu, SN Esatoğlu, E Gültürk, AE Eşkazan, G Hatemi, ...
Rheumatology 53 (6), 1136-1141, 2014
592014
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura
AE Eskazan
Annals of hematology 95 (11), 1751-1756, 2016
552016
New drugs approved for acute myeloid leukaemia in 2018
S Kucukyurt, AE Eskazan
British Journal of Clinical Pharmacology 85 (12), 2689-2693, 2019
512019
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
D Keskin, S Sadri, AE Eskazan
Drug design, development and therapy, 3355-3361, 2016
482016
Diyarbakır Eğitim Araştırma Hastanesi sağlık çalışanlarında kesici delici alet yaralanmalarının değerlendirilmesi
Ş Kaya, B Baysal, AE Eşkazan, H Çolak
Viral Hepatit Dergisi 18 (3), 107-10, 2012
482012
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
T Elverdi, AE Eskazan
Drug design, development and therapy, 1251-1258, 2019
452019
Spondylodiscitis: evaluation of patients in a tertiary hospital
S Kaya, S Ercan, S Kaya, U Aktas, K Kamasak, H Ozalp, K Cinar, ...
The Journal of Infection in Developing Countries 8 (10), 1272-1276, 2014
452014
Acute acalculous cholecystitis due to viral hepatitis A
S Kaya, AE Eskazan, N Ay, B Baysal, MV Bahadir, A Onur, R Duymus
Case reports in infectious diseases 2013, 2013
452013
Novel therapeutic approaches in chronic myeloid leukemia
NÖ Yurttaş, AE Eşkazan
Leukemia Research 91, 106337, 2020
442020
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion
AE Eskazan, D Eyice, EA Kurt, T Elverdi, FF Yalniz, A Salihoglu, MC Ar, ...
Leukemia Research 38 (7), 781-787, 2014
402014
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data …
S Ongoren, AE Eskazan, V Suzan, S Savci, I Erdogan Ozunal, S Berk, ...
Hematology 23 (4), 212-220, 2018
352018
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy
AE Eskazan, T Soysal, S Ongoren, E Gulturk, B Ferhanoglu, Y Aydin
Haematologica 96 (3), e15, 2011
352011
The impact of BCR‐ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia
A Ercaliskan, AE Eskazan
Cancer 124 (19), 3806-3818, 2018
342018
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
AE Eskazan, D Keskin
Therapeutic Advances in Hematology 8 (9), 237-243, 2017
312017
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate
AE Eskazan, M Ayer, B Kantarcioglu, D Arica, N Demirel, D Aydin, ...
British journal of haematology 167 (1), 139-141, 2014
302014
Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.
F Sahin, G Saydam, M Cömert, B Uz, AS Yavuz, E Turan, İ Yönal, H Atay, ...
Turkish Journal of Haematology: Official Journal of Turkish Society of …, 2013
292013
Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec
AE Eskazan, S Sadri, D Keskin, M Ayer, B Kantarcioglu, N Demirel, ...
Clinical Lymphoma Myeloma and Leukemia 17 (12), 804-811, 2017
282017
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20